Actinium Pharmaceuticals Unveils Preclinical Data for ATNM-400 in Breast Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Actinium Pharmaceuticals announced preclinical data for ATNM-400, a first-in-class Actinium-225 antibody radioconjugate, in hormone receptor positive, HER2 positive and triple-negative breast cancer that will be presented at the San Antonio Breast Cancer Symposium, SABCS, being held December10-14, 2025 in SanAntonio, Texas. The data demonstrates significant anti-tumor activity in breast cancer models resistant to standard-of-care therapies including endocrine therapy tamoxifen and HER2-targeted therapy trastuzumab as well as potent tumor growth inhibition in TNBC models. The data highlight ATNM-400's potential to address critical unmet needs in patients who have exhausted treatment options following endocrine therapy or HER2-targeted therapy failure. These data add to ATNM-400's robust preclinical data package that also encompasses metastatic castrate-resistant prostate cancer and non-small cell lung cancer.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ATNM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ATNM
Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.220
Low
4.00
Averages
6.00
High
9.00
Current: 1.220
Low
4.00
Averages
6.00
High
9.00
About ATNM
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
Continue Reading
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
- FibroBiologics Outperformance: FibroBiologics, Inc. (FBLG) surged 7.68% in after-hours trading to close at $0.41, indicating speculative interest or technical momentum despite no specific news.
- Nyxoah Earnings Boost Confidence: Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary Q4 and full-year 2025 results, with guidance for Q1 2026 enhancing investor confidence in its growth trajectory.
- Fortress Biotech's Continued Volatility: Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49 in after-hours trading, continuing a trend of volatility without any fresh news impacting the stock.
- Revvity Collaboration Drives Growth: Revvity, Inc. (RVTY) posted a 4.92% gain to close at $109.00, as investors digest the January announcement of a collaboration with Eli Lilly to expand access to predictive models via the Revvity Signals platform.
Continue Reading